AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29925499 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor (CAR)-modified T cells targeting CD19
Number of subjects: 0
Study 29925549 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonist (DA) use
Number of subjects: 411
Study 29925549 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonist (DA) discontinuation
Number of subjects: 411
Study 29925553 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide (Signifor; Signifor LAR)
Number of subjects: 1
Study 29925913 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant 5-ASA
Number of subjects: 2183
Study 29926156 — intervention group
Group type: EXPERIMENTAL
Intervention: Defined subclones (1 to 3 subclones)
Number of subjects: 1291
Study 29926156 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite karyotypes (CP)
Number of subjects: 1291
Study 29926156 — intervention group
Group type: COMPARATOR
Intervention: Defined subclones
Number of subjects: 1291
Study 29926288 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation in critically ill patients
Number of subjects: 12
Study 29926288 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood sampling at 12-hour intervals over a 5-day period
Number of subjects: 12
Study 29926288 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from eligibility to enrolment
Number of subjects: 12
Study 29926288 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from eligibility to the first blood sample
Number of subjects: 12
Study 29926288 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of plasma noradrenaline levels with norepinephrine dose
Number of subjects: 12
Study 29926400 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 50 mg/day for 20 weeks, then 50 or 100 mg/day for 32 weeks
Number of subjects: 103
Study 29926400 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 100 mg/day (for patients with insufficient control on 50 mg)
Number of subjects: 103
Study 29926400 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin and GLP-1 receptor agonists/sulfonylureas
Number of subjects: 103
Study 29926400 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Number of subjects: 103
Study 29926826 — intervention group
Group type: EXPERIMENTAL
Intervention: INET (intra-neuroendoscopic technique)
Number of subjects: 65
Study 29926826 — intervention group
Group type: COMPARATOR
Intervention: Control (extraventricular drainage plus urokinase thrombolytic therapy)
Number of subjects: 65
Study 29926892 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal handshake method
Number of subjects: 123
Study 29926892 — intervention group
Group type: COMPARATOR
Intervention: Simple palpation
Number of subjects: 123
Study 29927663 — intervention group
Group type: EXPERIMENTAL
Intervention: Accu-Chek
Number of subjects: 0
Study 29927663 — intervention group
Group type: EXPERIMENTAL
Intervention: System A
Number of subjects: 0
Study 29927663 — intervention group
Group type: EXPERIMENTAL
Intervention: System B
Number of subjects: 0
Study 29927663 — intervention group
Group type: EXPERIMENTAL
Intervention: System C
Number of subjects: 0
Study 29927663 — intervention group
Group type: EXPERIMENTAL
Intervention: System D
Number of subjects: 0
Study 29927663 — intervention group
Group type: EXPERIMENTAL
Intervention: All five systems
Number of subjects: 0
Study 29927663 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay-users
Number of subjects: 0
Study 29927663 — intervention group
Group type: EXPERIMENTAL
Intervention: Study personnel
Number of subjects: 0
Study 29927704 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 µg plague vaccine
Number of subjects: 240
Study 29927704 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 µg plague vaccine
Number of subjects: 240
Study 29927782 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-treatment group (15 months or less from diagnosis to cryoablation)
Number of subjects: 510
Study 29927782 — intervention group
Group type: COMPARATOR
Intervention: Late-treatment group (greater than 15 months from diagnosis to cryoablation)
Number of subjects: 510
Study 29927832 — intervention group
Group type: COMPARATOR
Intervention: Immediate DIEP flap reconstruction without postmastectomy radiotherapy
Number of subjects: 167
Study 29927832 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate DIEP flap reconstruction with postmastectomy radiotherapy
Number of subjects: 167
Study 29927832 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed reconstruction after simple mastectomy
Number of subjects: 167
Study 29927832 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastectomy with temporizing implant, postmastectomy radiotherapy, and DIEP flap reconstruction
Number of subjects: 167
Study 29927832 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate DIEP flap reconstruction or mastectomy with temporizing implant then DIEP flap surgery
Number of subjects: 167
Study 29928759 — intervention group
Group type: EXPERIMENTAL
Intervention: SST algorithm in Japanese patients
Number of subjects: 181
Study 29928759 — intervention group
Group type: EXPERIMENTAL
Intervention: SST algorithm in Japanese patients after propensity score matching
Number of subjects: 181
Study 29928759 — intervention group
Group type: COMPARATOR
Intervention: SST algorithm in other geographies (OJPN)
Number of subjects: 181
Study 29929047 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal exposure to phenylurea herbicide isoproturon
Number of subjects: 25
Study 29929047 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal exposure to phenoxyherbicide 2-methyl-4-chlorophenoxyacetic acid
Number of subjects: 25
Study 29929092 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with doxorubicin (60 mg/m²) and ifosfamide for six cycles
Number of subjects: 150
Study 29929092 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with doxorubicin and ifosfamide
Number of subjects: 150
Study 29929491 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (NET inhibitor)
Number of subjects: 0
Study 29929491 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (part of preoperative chemotherapy)
Number of subjects: 0
Study 29929493 — intervention group
Group type: EXPERIMENTAL
Intervention: self-hypnosis/self-care group intervention
Number of subjects: 93
Study 29929514 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescent Spot Test (FST)
Number of subjects: 1262
Study 29929514 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Test (RDT)
Number of subjects: 1262
Study 29929514 — intervention group
Group type: COMPARATOR
Intervention: RDT compared to FST
Number of subjects: 1262
Study 29930021 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (standard regimen)
Number of subjects: 180
Study 29930021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg (T90)
Number of subjects: 180
Study 29930021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg (T60)
Number of subjects: 180
Study 29930021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (T60 or T90)
Number of subjects: 180
Study 29930943 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 77
Study 29930943 — intervention group
Group type: COMPARATOR
Intervention: Copeptin
Number of subjects: 77
Study 29930943 — intervention group
Group type: COMPARATOR
Intervention: hs-cTnT
Number of subjects: 77
Study 29931040 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate intake <1/mo
Number of subjects: 83310
Study 29931040 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate intake 1 to <1.5/mo
Number of subjects: 83310
Study 29931040 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate intake 1.5 to <3.5/mo
Number of subjects: 83310
Study 29931040 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate intake 3.5/mo to <3/wk
Number of subjects: 83310
Study 29931040 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate intake ≥3/wk
Number of subjects: 83310
Study 29931040 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate intake (combined for age <65 y)
Number of subjects: 83310
Study 29931040 — intervention group
Group type: COMPARATOR
Intervention: Chocolate intake and risk of CHD
Number of subjects: 83310
Study 29931040 — intervention group
Group type: COMPARATOR
Intervention: Chocolate intake and risk of stroke
Number of subjects: 83310
Study 29931040 — intervention group
Group type: COMPARATOR
Intervention: Chocolate intake and risk of CHD and stroke combined
Number of subjects: 83310
Study 29931040 — intervention group
Group type: EXPERIMENTAL
Intervention: Age modification effect
Number of subjects: 83310
Study 29931068 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-Hydroxyvitamin D deficiency (<20 ng/mL)
Number of subjects: 6302
Study 29931068 — intervention group
Group type: COMPARATOR
Intervention: 25-Hydroxyvitamin D replete (≥30 ng/mL)
Number of subjects: 6302
Study 29931248 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile 3D annuloplasty ring
Number of subjects: 148
Study 29931424 — intervention group
Group type: EXPERIMENTAL
Intervention: 72-hour fasting
Number of subjects: 0
Study 29931453 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 50 mg qn for 3 months
Number of subjects: 0
Study 29931812 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial triglycerides (PPTGs) measured at 1-hour and 2-hour after a controlled liquid breakfast
Number of subjects: 54
Study 29931812 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting triglycerides (TGs)
Number of subjects: 54
Study 29931812 — intervention group
Group type: COMPARATOR
Intervention: Increase in TGs from early to later pregnancy
Number of subjects: 54
Study 29931812 — intervention group
Group type: COMPARATOR
Intervention: Maternal glucose
Number of subjects: 54
Study 29932498 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured light plethysmography (SLP) before bronchodilator treatment
Number of subjects: 39
Study 29932498 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured light plethysmography (SLP) after bronchodilator treatment
Number of subjects: 39
Study 29932498 — intervention group
Group type: COMPARATOR
Intervention: Structured light plethysmography (SLP) in healthy children
Number of subjects: 39
Study 29933073 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-486 (200 mg, n=3; 300 mg, n=4) once daily for 7 days per cycle
Number of subjects: 30
Study 29933073 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-486 (150 mg, n=4; 200 mg, n=19) for 14 days per cycle
Number of subjects: 30
Study 29933073 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-486 maintenance therapy
Number of subjects: 30
Study 29933095 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg orally, twice daily) combined with gemcitabine (1000 mg/m2) and cisplatin chemotherapy
Number of subjects: 26
Study 29933096 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF) 25 mg once daily
Number of subjects: 1298
Study 29933096 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg once daily
Number of subjects: 1298
Study 29933267 — intervention group
Group type: EXPERIMENTAL
Intervention: GA + neuraxial anesthesia
Number of subjects: 9442
Study 29933267 — intervention group
Group type: COMPARATOR
Intervention: GA only
Number of subjects: 9442
Study 29933267 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusions
Number of subjects: 9442
Study 29933267 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery in a rural hospital
Number of subjects: 9442
Study 29933272 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion at target plasma concentrations of 0.3, 0.6, 1.2, and 2.4 ng/mL
Number of subjects: 16
Study 29933272 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 16
Study 29933761 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (nCRT) followed by minimally-invasive robotic surgery
Number of subjects: 0
Study 29933761 — intervention group
Group type: EXPERIMENTAL
Intervention: BH3 profiling and metabolomics
Number of subjects: 0
Study 29933761 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard evaluation including CT scans, laboratory tests, endoscopy with biopsies
Number of subjects: 0
Study 29933912 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transplantation (xdcfDNA percentage)
Number of subjects: 7
Study 29933912 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transplantation (xdcfDNA levels)
Number of subjects: 7
Study 29933912 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevations in xdcfDNA percentage
Number of subjects: 7
Study 29934373 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR/EULAR Boolean remission (44 joints)
Number of subjects: 103
Study 29934373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound power Doppler remission
Number of subjects: 103
Study 29934373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound grey scale remission
Number of subjects: 103
Study 29934373 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical remission criteria
Number of subjects: 103
Study 29934373 — intervention group
Group type: COMPARATOR
Intervention: No remission criteria
Number of subjects: 103
Study 29934383 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1000
Study 29934393 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoperfusion (HP)
Number of subjects: 360
Study 29934393 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis (HD)
Number of subjects: 360
Study 29934393 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent HP-HD
Number of subjects: 360
Study 29934393 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 360
Study 29934393 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (HP, HD, concurrent HP-HD, Control)
Number of subjects: 360
Study 29934394 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise prehabilitation
Number of subjects: 0
Study 29934394 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 29934395 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (M)
Number of subjects: 400
Study 29934395 — intervention group
Group type: COMPARATOR
Intervention: Hydromorphone (HM)
Number of subjects: 400
Study 29934438 — intervention group
Group type: EXPERIMENTAL
Intervention: LTA agonist and native LGG
Number of subjects: 0
Study 29934438 — intervention group
Group type: EXPERIMENTAL
Intervention: LGG with a mutation in the processing of lipoteichoic acid (LTA)
Number of subjects: 0
Study 29934438 — intervention group
Group type: EXPERIMENTAL
Intervention: LGG given by gavage
Number of subjects: 0
Study 29934438 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate liposomes (macrophage depletion)
Number of subjects: 0
Study 29934438 — intervention group
Group type: EXPERIMENTAL
Intervention: LTA in fractionated radiation regimens
Number of subjects: 0
Study 29934438 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCR4 agonist
Number of subjects: 0
Study 29934842 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent Iodine-125 Seed Implantation, median biologically effective dose (BED) about 180 Gy
Number of subjects: 2316
Study 29934842 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent Iodine-125 Seed Implantation
Number of subjects: 2316
Study 29934885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance imaging (CMR) assessment of pulmonary artery (PA) stiffness, measuring pulsatility, distensibility, compliance, and capacitance.
Number of subjects: 51
Study 29934885 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (n=18)
Number of subjects: 51
Study 29935107 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary α-linolenic acid (ALA) intake
Number of subjects: 15100
Study 29935107 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary linoleic acid (LA) intake
Number of subjects: 15100
Study 29935107 — intervention group
Group type: EXPERIMENTAL
Intervention: LA- or ALA-enriched high-fat diet (HFD) in DIO mice
Number of subjects: 15100
Study 29935143 — intervention group
Group type: EXPERIMENTAL
Intervention: Early capsule endoscopy
Number of subjects: 87
Study 29935143 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 87
Study 29935153 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrotactile feedback (VTF) in a dark room
Number of subjects: 12
Study 29935153 — intervention group
Group type: COMPARATOR
Intervention: No vibrotactile feedback (Control) in a dark room
Number of subjects: 12
Study 29935381 — intervention group
Group type: EXPERIMENTAL
Intervention: East/South East Asian ethnicity
Number of subjects: 1594
Study 29935441 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased cognitive control through neural recruitment during the affective stroop task (fMRI)
Number of subjects: 21
Study 29935441 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased BOLD response over time to emotional relative to neutral stimuli in inferior parietal cortex
Number of subjects: 21
Study 29935441 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 21
Study 29935581 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 47
Study 29935581 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 47
Study 29935596 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal intubation
Number of subjects: 31024
Study 29935596 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraglottic airway insertion
Number of subjects: 31024
Study 29935596 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult airway management
Number of subjects: 31024
Study 29935810 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrioma group
Number of subjects: 80
Study 29935810 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 29935810 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrioma group (AFC)
Number of subjects: 80
Study 29936063 — intervention group
Group type: EXPERIMENTAL
Intervention: IMAB362 (Zolbetuximab) 33, 100, 300, 600, and 1000 mg/m2 single dose
Number of subjects: 15
Study 29936063 — intervention group
Group type: EXPERIMENTAL
Intervention: IMAB362 (Zolbetuximab) 600 mg/m2 single dose
Number of subjects: 15
Study 29936063 — intervention group
Group type: EXPERIMENTAL
Intervention: IMAB362 (Zolbetuximab)
Number of subjects: 15
Study 29936064 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 120 mg/m²
Number of subjects: 64
Study 29936064 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 240 mg/m²
Number of subjects: 64
Study 29936086 — intervention group
Group type: COMPARATOR
Intervention: Prior diabetes treatment assignment
Number of subjects: 453
Study 29936086 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic control over time
Number of subjects: 453
Study 29936086 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, race-ethnicity, sex, higher blood pressure and BMI
Number of subjects: 453
Study 29936086 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting blood pressure and obesity
Number of subjects: 453
Study 29936086 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial stiffness measurement
Number of subjects: 453
Study 29936327 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous electronic cardiorespiratory monitoring (CEM) using pulse oximetry and capnography
Number of subjects: 1650
Study 29936327 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous electronic cardiorespiratory monitoring (CEM)
Number of subjects: 1650
Study 29936438 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 0
Study 29936438 — intervention group
Group type: COMPARATOR
Intervention: TNFi monotherapy
Number of subjects: 0
Study 29936535 — intervention group
Group type: EXPERIMENTAL
Intervention: Teff injera consumption (TI) - everyday consumption
Number of subjects: 592
Study 29936535 — intervention group
Group type: EXPERIMENTAL
Intervention: Teff injera consumption (TI) - every other day
Number of subjects: 592
Study 29936535 — intervention group
Group type: EXPERIMENTAL
Intervention: Teff injera consumption (TI) - 1-2 times a week
Number of subjects: 592
Study 29936535 — intervention group
Group type: EXPERIMENTAL
Intervention: Teff injera consumption (TI) - once in 2 weeks
Number of subjects: 592
Study 29937300 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided revascularisation deferral
Number of subjects: 292
Study 29937325 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 336
Study 29937365 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric laser endomicroscopy (VLE)
Number of subjects: 10
Study 29938395 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (E), Trastuzumab (T), and Vinorelbine (V)
Number of subjects: 32
Study 29938772 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly ixazomib 3·0 mg plus lenalidomide 25 mg and dexamethasone 20 mg (10 mg in cycles 9-16) for up to sixteen 21-day cycles, followed by maintenance with twice-weekly ixazomib alone.
Number of subjects: 64
Study 29938772 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly ixazomib-Rd
Number of subjects: 64
Study 29938825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood insulin
Number of subjects: 162
Study 29938825 — intervention group
Group type: COMPARATOR
Intervention: Maternal metabolic indices
Number of subjects: 162
Study 29939053 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment-Based Family Therapy (ABFT)
Number of subjects: 129
Study 29939053 — intervention group
Group type: COMPARATOR
Intervention: Family-Enhanced Nondirective Supportive Therapy (FE-NST)
Number of subjects: 129
Study 29939981 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion-based attention task
Number of subjects: 0
Study 29939981 — intervention group
Group type: EXPERIMENTAL
Intervention: Color-based attention task
Number of subjects: 0
Study 29939981 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective connectivity analysis using DCM
Number of subjects: 0
Study 29939981 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective connectivity analysis using GCM
Number of subjects: 0
Study 29940167 — intervention group
Group type: EXPERIMENTAL
Intervention: Argus II retinal prosthesis implantation
Number of subjects: 33
Study 29940251 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperineal template prostate mapping biopsy
Number of subjects: 249